

Traverse Therapeutics

Investor Fact Sheet

At Traverse Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.

Ticker	TVTX
Market Cap (B)¹	\$4.1
Shares Outst (M)²	92.4
Cash (M)³	\$265

¹ As of 5/1/26. ² As of 3/31/26. ³ Cash, cash equivalents and marketable securities as of March 31, 2026.

Strategic Priorities to Drive Significant Growth Now and in the Future



Reinforce FILSPARI's **foundational position** in a growing IgAN market



Successfully launch **FILSPARI in FSGS**



Position **pegtibatinase** as the first potential disease-modifying therapy in HCU

FILSPARI: Significant Growth Opportunity with Strong Commercial Synergies Across IgAN and FSGS



>100,000

addressable patients with IgAN and FSGS in the U.S.¹



>\$3B

total commercial opportunity for FILSPARI in the U.S.



~7,000

target prescribers treating most patients with IgAN and FSGS



>80%

overlap between IgAN and FSGS prescribers²

¹ Source: Estimated based on independent market research and data on file.

² Source: Traverse market research.

FILSPARI Positioned as a First-in-Class Foundational Treatment in IgAN



Streamlined liver monitoring



One pill, once daily administration



Two-year safety data comparable to maximum-labeled dose irbesartan



FILSPARI[®]

stronger foundation for kidney preservation



Superior two-year proteinuria reduction vs active comparator irbesartan

Flexibility for combination use and newly diagnosed patients with IgAN



Only therapy to date to demonstrate statistically significant slowing of kidney function decline in a Phase 3 study vs active comparator irbesartan



